Biohackr: Track your protocol. Model the curve.

Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.

Overview

Epitalon (also spelled Epithalon or Epithalone, with the formal designation AEDG peptide) is a synthetic tetrapeptide (4 amino acids) with the sequence Ala-Glu-Asp-Gly. At molecular weight 390.35 Da it is the smallest peptide in this library and one of the smallest bioactive peptides studied for longevity applications. It was developed by Russian gerontologist Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s–1990s, derived from epithalamin (a polypeptide extract from bovine pineal gland) through identification of the minimum bioactive fragment.

Epitalon belongs to a distinctive research tradition: the Russian peptide bioregulator program. Where Selank ([[selank]]) and Semax ([[semax]]) are oriented toward neurological/neuropsychiatric applications and have Russian Federation marketing approval, Epitalon belongs to the gerontology and anti-aging branch of Khavinson's broader peptide bioregulator framework, and does not have formal Russian regulatory approval. It is research-stage even within the Russian context.

The defining scientific claim about Epitalon (and the one that generates most attention in Western longevity circles) is that this four-amino-acid peptide can activate telomerase, lengthen telomeres, and modulate cellular aging markers. This is a substantial claim. Unlike many longevity marketing stories, it is tethered to real if methodologically limited research spanning three decades: the foundational Khavinson 2003 paper demonstrated telomerase induction and telomere elongation in human fetal fibroblast and adult lung fibroblast cultures; the more recent Al-Dulaimi 2025 paper (PMC 12411320) is an independent Western replication confirming telomere lengthening across multiple human cell lines through either telomerase upregulation or alternative lengthening of telomeres (ALT) activity.

The research tradition matters. The Khavinson program represents a fundamentally different paradigm from Western 'single target, single mechanism' pharmaceutical development. The concept: tissue-specific short peptides regulate organ-specific gene expression and counteract age-related decline; declining production of these endogenous bioregulators contributes to aging; exogenous administration may compensate. This framework produced multiple related peptides: Thymalin (thymus-derived, immune), Vilon (Lys-Glu dipeptide), Cortexin (brain-derived, cognitive), Pinealon (pineal-related), Cortagen. Many of these have substantial Russian research literatures but limited Western validation.

What sets Epitalon apart from most peptides in this library is the theoretical framework it comes from rather than any property of the molecule. The Khavinson program conceptualizes it as a bioregulator whose role is to restore endogenous signaling patterns, not to sustain a pharmacological override of a receptor system. No regulatory authority anywhere has approved Epitalon for any indication, so nothing published about how it has been administered constitutes a validated regimen.

Forms

Available forms & half-lives

Form	Approximate half-life
Subcutaneous Epitalon	Very short (~30 min for parent peptide)
Intranasal Epitalon	Variable
Oral Epitalon	Not feasible

What it does

Main effects

Telomerase activation · Central claim; demonstrated in human fetal fibroblast and adult lung fibroblast cultures (Khavinson 2003); independently replicated in a Western 2025 paper (Al-Dulaimi 2025, PMC 12411320) confirming telomere lengthening across multiple human cell lines via either telomerase upregulation or alternative lengthening of telomeres (ALT) activity
Telomere length extension · Documented in cell line studies; the mechanistic basis for longevity claims
Pineal–melatonin axis modulation · Restoration of melatonin secretion patterns documented in aged monkeys; circadian rhythm normalization observed in Russian aging research
Lifespan extension in rodent models · Multiple Russian studies in mice and rats; not replicated at scale in Western longevity programs
Antioxidant activity · Documented across multiple systems
Neuroendocrine normalization in senescent animals · Russian preclinical evidence in monkey aging models
Retinal protection · Studies in age-related retinal degeneration models

What to watch for

Common side effects

Generally clean safety profile · No major adverse events documented in Russian or international research at the exposures studied; one of the more benign safety profiles in the peptide literature
Theoretical cancer concern from telomerase mechanism · Telomerase activation is a hallmark of many cancers (Hanahan & Weinberg cancer hallmarks); systemic telomerase activation raises theoretical malignancy risk; Russian research has paradoxically reported reduced cancer incidence in treated cohorts, but Western independent replication of this safety claim is lacking; the theoretical concern remains unresolved
Evidence asymmetry: Russian vs Western paradigms · The vast majority of clinical data is from Russian research with methodological characteristics that differ from Western GCP standards (smaller sample sizes, varying randomization rigor, often open-label designs, Russian-language publication); one independent Western cell-line replication (2025) exists but no Western RCTs
Russian peptide bioregulator framework · Differs fundamentally from Western 'single target, single mechanism' pharmaceutical paradigms; users should understand this is a different research tradition with different validation standards, not a fully Western-validated therapy
Mild injection-site reactions · Standard for SC peptide administration
Research chemical quality concerns · No pharmaceutical-grade source in most jurisdictions; identity, concentration, sterility unverified across the supply chain
Long-term human safety data lacking · Even within Russian research, decades-long human follow-up is limited; the theoretical telomerase-cancer concern cannot be confidently excluded by available data
Not WADA-prohibited (verify current status before use in tested sport)
Not on FDA bulk drug substance lists for compounding; not legally available through US 503A/503B compounding pharmacies

Key facts

Key facts worth knowing

Epitalon is a synthetic tetrapeptide with sequence Ala-Glu-Asp-Gly (AEDG). Just 4 amino acids, far smaller than typical peptides. Molecular weight 390.35 Da. CAS 307297-39-8. The small size facilitates synthesis and may enable unusual delivery routes that aren't viable for larger peptides.
Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology: Khavinson developed Epitalon in the 1980s–1990s and has published 100+ papers on Epitalon and related peptide bioregulators over his career. He is the central figure in this research tradition. The Institute represents one of the longest-running gerontology-focused research programs anywhere.
Derived from Epithalamin (bovine pineal extract). Epithalamin was a polypeptide extract from bovine pineal gland that showed anti-aging properties in earlier Soviet research. Khavinson's team identified the minimum bioactive fragment within epithalamin as the AEDG tetrapeptide, a classical pharmacological identification process applied within the Russian tissue-extract tradition.
Khavinson 2003: the foundational telomerase paper. Demonstrated that Epitalon induced telomerase activity and telomere elongation in human fetal fibroblast and adult lung fibroblast cultures. This is the cornerstone paper for the telomerase activation claim. Methodology was cell-culture rather than human-in-vivo; replication was limited for ~20 years. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine 2003;135(6):590-2.
Al-Dulaimi 2025 (PMC 12411320): independent Western replication. A more recent independent paper confirming telomere lengthening across multiple human cell lines through either telomerase upregulation or alternative lengthening of telomeres (ALT) activity. This is the most consequential independent replication of the Khavinson 2003 finding and substantially elevates the credibility of the telomere lengthening claim. PMC: 12411320Al-Dulaimi et al. 2025. Epitalon (AEDG) effects on telomere lengthening across human cell lines: independent replication. PMC 12411320.
Pineal gland origin matters. The pineal gland produces melatonin and has been associated with aging regulation since the 1950s–60s. Russian gerontology has had particular interest in pineal-derived therapeutics. The hypothesis: pineal peptides regulate circadian rhythms and contribute to age-related decline when they decrease; exogenous AEDG may compensate. Russian research has documented melatonin secretion restoration in aged monkeys treated with Epitalon.
No validated regimen exists. No regulatory authority anywhere, including in Russia, has approved Epitalon for any indication, so no dose, route or duration of exposure has been established for it. The Khavinson program's own framework treats these peptides as bioregulators meant to restore endogenous patterns rather than to sustain a pharmacological override, but that is a theoretical position rather than a validated one.
Russian peptide bioregulator family: Related Khavinson program peptides include Thymalin (thymus-derived, immune function), Vilon (Lys-Glu dipeptide), Cortagen, Cortexin (brain-derived, cognitive applications), and Pinealon (related pineal peptide). Most have substantial Russian research literatures and limited Western validation. Selank and Semax, also Russian peptides in this library, come from a different (neuropsychiatric) branch and have Russian Federation marketing approval; Epitalon does NOT have formal Russian approval.
The theoretical cancer concern is the central safety question. Telomerase activation is among the recognized hallmarks of cancer (Hanahan & Weinberg). Any therapy that activates telomerase systemically raises theoretical malignancy risk. Russian research has paradoxically reported reduced cancer incidence in treated cohorts, but Western replication of this safety finding is lacking. The theoretical concern cannot be confidently excluded by available data and should factor into any individual risk-benefit assessment.
Evidence asymmetry: Russian vs Western paradigms. Russian research uses methodologies that differ from Western GCP standards: smaller sample sizes; varying randomization rigor; often open-label designs; Russian-language publication that limits global review. This is not a dismissal of the research. It is a fundamentally different paradigm with different validation conventions. Western readers should calibrate accordingly: the body of evidence is real, but not equivalent to Phase 3 RCT-level validation that Western pharmaceuticals require.

Legal status